| Company Name: | Abaxis, Inc. | | Ticker Symbol: | ABAX | | | WWW Address: | www.abaxis.com |
| CEO: | Mr. Clinton H. Severson | | No. of Employees: | 491 |
| Common Issue Type: | CS | | Business Description: | Abaxis, Inc. develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements.
|
| | | Industry Information: | DRUGS - Diagnostic Support [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 43.67 |  0.15 | 43.65 | 43.68 | 43.35 | 44.07 | 42.93 | 45623 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 965.2 | 22.1 | 1.10 | 1.23 | 1.00 | 35.4 | 0.0 | 49.45 - 31.04 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 43.53 | $ | | PE Ratio - LTM | 35.4 | |
| Market Capitalisation | 965.2 | mil |
| Latest Shares Outstanding | 22.1 | mil |
| Earnings pS (EPS) | 1.23 | $ |
| Dividend pS (DPS) | 1.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 81 | % |
| Revenue per Employee | | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 17.1 | mil |
| Float as % of Shares Outstanding | 77.8 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 7.50 | % |
| Gross Profit Margin | 57.1 | % |
| EBITDA Margin | 16.2 | % |
| Pre-Tax Profit Margin | 22.6 | % |
| Assets Turnover | 1.0 | % |
| Return on Assets (ROA) | 13.0 | % |
| Return on Equity (ROE) | 15.4 | % |
| Return on Capital Invested (ROCI) | 15.3 | % |
| Current Ratio | 5.7 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 176.5 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 5.33 | $ |
| Cash pS | 2.15 | $ |
| Book-Value pS | 7.50 | $ |
| Tangible Book-Value pS | 7.34 | $ |
| Cash Flow pS | 1.45 | $ |
| Free Cash Flow pS | 0.12 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.81 | |
| Price/Tangible Book Ratio | 5.93 | |
| Price/Cash Flow | 29.9 | |
| Price/Free Cash Flow | 354.8 | |
| P/E as % of Industry Group | 134.0 | % |
| P/E as % of Sector Segment | 58.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 12/05/2012 |
| Dividend Ex-Date | 12/12/2012 |
| Dividend Record Date | 12/16/2012 |
| Dividend Pay Date | 12/27/2012 |
| Dividend Amount | 1000 |
| Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 81.0 |
| 5-Y Average Payout Ratio | 16.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -4.0 | 97 | 1,693 | 6,407 |
| 4 Weeks | 47.25 | 41.40 | 41.34 | 5.3 | 101 | 1,755 | 33,344 |
| 13 Weeks | 49.45 | 40.48 | 43.52 | 0.0 | 92 | 1,598 | 100,681 |
| 26 Weeks | 49.45 | 35.13 | 36.78 | 18.4 | 101 | 1,437 | 178,169 |
| 52 Weeks | 49.45 | 31.04 | 32.56 | 33.7 | 107 | 1,285 | 318,666 |
| YTD | 49.45 | 37.00 | - | 17.3 | 101 | 1,552 | 153,685 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 44.26 | 45.35 | 45.55 | 41.63 | 40.31 | 1.10 | 1.18 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 13.40 | 98.5 | 13.76 |
| Income | 12.90 | 52.7 | 24.07 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 18.58 | NA | 7.38 |
| R&D | 14.49 | NA | 9.43 |
| Normalized Inc. | -3.75 | NA | -10.39 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 18.8 | 16.9 | 9.0 |
| Earnings % | 109.8 | 42.3 | 109.8 |
| EPS % | 112.1 | 42.9 | 112.1 |
| EPS $ | 0.65 | 0.09 | 0.65 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 65.89 |
| Current Ratio | 7.6 |
| Quick Ratio (Acid Test) | 5.9 |
| Liquidity Ratio (Cash) | 3.91 |
| Receivables Turnover | 5.3 |
| Average Collection Period | 68 |
| Working Capital/Equity | 75.5 |
| Working Capital pS | 6.02 |
| Cash-Flow pS | 0.00 |
| Free Cash-Flow pS | 0.00 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 24.96 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 12.7 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 3.1 |
| LT Debt/Total Liabilities | 2.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.78 |
| Tobin's Q Ratio | 4.77 |
| Current P/E Ratio - LTM | 35.40 |
| Enterprise Value (EV)/EBITDA | 36.54 |
| Enterprise Value (EV)/Free Cash Flow | 0.00 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 5.93 |
| Price/Book Ratio - LTM | 5.81 |
| Price/Cash Flow Ratio | 29.9 |
| Price/Free Cash Flow Ratio - LTM | 354.8 |
| Price/Sales Ratio | 5.17 |
| P/E Ratio (1 month ago) - LTM | 36.3 |
| P/E Ratio (26 weeks ago) - LTM | 35.0 |
| P/E Ratio (52 weeks ago) - LTM | 56.1 |
| 5-Y High P/E Ratio | 56.7 |
| 5-Y Low P/E Ratio | 18.8 |
| 5-Y Average P/E Ratio | 42.5 |
| Current P/E Ratio as % of 5-Y Average P/E | 83 |
| P/E as % of Industry Group | 134.0 |
| P/E as % of Sector Segment | 58.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 118.3 |
| PER SHARE FIGURES |
| LT Debt pS | 0.03 |
| Current Liabilities pS | 0.91 |
| Tangible Book Value pS - LTM | 7.34 |
| Book Value pS - LTM | 7.50 |
| Capital Invested pS | 8.00 |
| Cash pS - LTM | 2.15 |
| Cash Flow pS - LTM | 1.45 |
| Free Cash Flow pS - LTM | 0.12 |
| Earnings pS (EPS) | 1.23 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.00 |
| Free Cash Flow Margin 5YEAR AVG | 7.50 |
| Net Profit Margin | 14.8 |
| Net Profit Margin - 5YEAR AVRG. | 11.2 |
| Equity Productivity | 1.06 |
| Return on Equity (ROE) | 15.6 |
| Return on Equity (ROE) - 5YEAR AVRG. | 9.2 |
| Capital Invested Productivity | 1.05 |
| Return on Capital Invested (ROCI) | 15.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 9.2 |
| Assets Productivity | 1.00 |
| Return on Assets (ROA) | 13.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | 8.2 |
| Gross Profit Margin | 57.1 |
| Gross Profit Margin - 5YEAR AVRG. | 59.4 |
| EBITDA Margin - LTM | 16.2 |
| EBIT Margin - LTM | 22.7 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 16.5 |
| Effective Tax Rate | 35.2 |
| Effective Tax Rate - 5YEAR AVRG. | 37.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 77 |
| Revenue per Employee | |
| Net Income per Employee | |
| Average Collection Period | 77 |
| Receivables Turnover | 5.3 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 14.4 |
| Accounts Payble/Sales | 4.37 |
| Assets/Revenue | 1.00 |
| Net Working Capital Turnover | 1.40 |
| Fixed Assets Turnover | 3.81 |
| Total Assets Turnover | 1.0 |
| Revenue per $ Cash | 3.39 |
| Revenue per $ Plant | 7.34 |
| Revenue per $ Common Equity | 1.06 |
| Revenue per $ Capital Invested | 1.05 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 32.1 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |
